Angiomatoid fibrous histiocytoma may arise in any region of the body, including the head, neck, trunk, and lung, but most commonly arises in the extremities [2, 6, 8, 9]. It also occasionally arises in subcutaneous regions, so non-specialized surgeons often undertake unplanned resection [7]. We present the first case of subcutaneous AFH in the iliac region treated with a previous improper resection by a non-specialized surgeon.
The onset age of the current case was similar to that of previously described cases [10]. Subcutaneous AFH in the iliac region is extremely rare. According to previous reports, it is possible that it originates from the fibroblastic reticulum of the interstitium of normal lymph nodes [2, 4]. In the current case, it is possible that the origin of the tumor was the external iliac lymph node. The presence of systemic symptoms, such as weight loss, malaise, fever, and anemia [10,11,12], which occur in some patients, can aid diagnosis. However, in the current case, the patient experienced no systemic symptoms. Some groups have reported MRI features of AFH, including cystic areas, pseudocapsules, edema of surrounding mass, enhancement, and fluid–fluid levels [10,11,12], which were observed in the current case. Although the MRI features of AFH described in the literature may aid diagnosis [6, 13], none of them are considered to be significant [10]. The characteristic histological features of AFH have been well described [2]. This includes the following features: (i) multinodular growth of myoid spindle or histiocytoid cells with a distinctive syncytial appearance, (ii) pseudoangiomatous spaces filled with blood and surrounded by tumor cells, (iii) a thick fibrous pseudocapsule with prominent hemosiderin deposition, and (iv) peritumoral lymphoplasmacytic cuffing with occasional germinal center formation. Other immunohistochemical features of AFH include the fact that approximately half of AFH tumors have desmin expression, which may be diffuse or focal, and occasionally exhibit expression of other markers of myoid differentiation such as smooth muscle actin, calponin, and rarely h-caldesmon [2]. Reports on the expression of epithelial membrane antigen, CD99, and CD68 have varied [2,3,4,5]. AFH is also indicated by the negative expression of certain markers, which often include skeletal muscle markers, such as myogenin and MyoD, vascular endothelial markers, such as CD31 and CD34, factor VIII-related antigen, CD35, S-100 protein, and cytokeratins [2]. For differential diagnosis, it is often necessary to differentiate AFH from synovial sarcoma because the current histology revealed proliferation of spindle cells. We ruled out a diagnosis of synovial sarcoma based on H–E staining features and negative immunostaining for S-100 and CD34. AFH should also be differentially diagnosed from other soft tissue tumors like aneurysmal benign fibrous histiocytoma, palisaded lymph node myofibroblastoma, and follicular dendritic cell sarcoma [14]. We could differentiate AFH from those tumors by H–E staining features without immunohistochemistry. In the current case, a confirmative diagnosis of AFH was provided by comprehensive analysis. We were unable to examine the presence of fusion genes that have been associated with AFH. EWSR1-CREB1 is the most frequently described gene fusion to date, having been described in more than 90% of cases [15, 16], although EWSR1-ATF1 appears to be more common in AFH that occurs in extra-somatic soft tissue sites [15,16,17]. FUS-ATF1 has been described least commonly [17].
The prognosis of AFH is generally considered to be favorable [2, 7, 8]. A previous study showed that recurrence occurred in 25% of cases, metastasis occurred in 5%, and death occurred in 5% [18]. However, another study reported that 63% and 21% of patients had local recurrence and metastasis, respectively, and that 12% of patients died due to the disease [19]. In general, soft tissue tumors, particularly sarcomas, should be considered for treatment by a specialized surgeon [20]. Furthermore, extended resection of AFH is recommended because the tumor is considered intermediate [6]. Additionally, if an unplanned resection has been undertaken, the sarcoma should be treated with additional extended resection [21], as was performed in the current study. With such treatment, functional disorder will occur after surgery [22]. In our patient, perceptual disorders of the femoral front remained.
There were some limitations in the current study. First, we did not perform immunohistochemistry for desmin, which is often useful for differential diagnosis. However, we could make a diagnosis without desmin in the current case. Second, we did not examine fusion genes, although we could confirm the diagnosis of AFH without such an analysis. In conclusion, treating clinicians should consider the possibility of AFH when presented with a subcutaneous mass to avoid unplanned resection.